Depressive DisorderPhase 2NCT03932825
Nitrous Oxide for Major Depressive Disorder
A Phase 2 study testing Nitrous Oxide in people with Depressive Disorder and Major Depressive Disorder, run by Lingjiang Li at 1 site in China.
Trial summary
This study aims at investigating the persistence of antidepressant effect of Nitrous Oxide (N2O) for Treatment-Resistant Depression(TRD). The investigators also aim to assess the effect of N2O on the electroencephalograph, multimodal magnetic resonance imaging(MRI), blood cytokines, feces bacteria flora and… Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Depressive Disorder, Major Depressive Disorder, Treatment Resistant Depression
- What is being tested?
- Nitrous Oxide
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 44 participants
- Where
- 1 siteChina
- Study dates
- 1 Apr 2019to 31 Mar 2021
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Adult (≥18 years, both sexes), with ICD-10 criteria for MDD without psychosis, as determined by a structured clinical interview Mini International Neuropsychiatric Interview
- Moderate to severe depression, as defined by a pretreatment score >17 on the HDRS-17 scale
- TRD was defined as having had at least two adequate dose-duration, antidepressant medication failures in the current episode and a lifetime failure of at least three antidepressant medication trials.
- Informed consent to participate in this study
Who cannot join
- A history of bipolar disorder, schizophrenia, schizoaffective disorder, obsessive-compulsive disorder, panic disorder, or documented Axis II diagnoses; active suicidal intention, as determined by clinical interview
- Active or recent (<12 months) substance abuse or dependence; excluding nicotine
- Presence of acute medical illness that could interfere with study participation, including significant pulmonary disease
- Acute severe suicidal ideation
- Acute psychosis
- Received ECT treatment within 6 months
Show all 9Show fewer
- History of NMDA-antagonists (e.g., ketamine) intake
- Pregnancy or breastfeeding
- Any contraindications to the use of nitrous oxide (e.g., pneumothorax, middle ear occlusion, elevated intracranial pressure, chronic cobalamin or folate deficiency unless treated with folic acid or vitamin B12).
Trial locations and contacts
1 site in 1 country.
China1 site
Mental Health Institute & Faculty of Psychiatry of The Second Xiangya Hospital, Central South University
Changsha, Hunan, 410001
About this study
Official title: A Clinical Trial of Nitrous Oxide for Treatment-Resistant Major Depressive Disorder
This study aims at investigating the persistence of antidepressant effect of Nitrous Oxide (N2O) for Treatment-Resistant Depression(TRD). The investigators also aim to assess the effect of N2O on the electroencephalograph, multimodal magnetic resonance imaging(MRI), blood cytokines, feces bacteria flora and neuropsychological performance in patients with TRD. The investigators further aim to identify the predictors of N2O's antidepressant effeect using the above techniques.
- Conditions
- Depressive Disorder, Major Depressive Disorder, Treatment Resistant Depression, Depressive Disorder, Major, Depression
- Being tested
- Nitrous Oxide, Placebo
- Keywords
- Nitrous Oxide, Laughing Gas
- Medical subject headings
- Depressive Disorder, Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant, Depression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nitrous OxideDrug
Also called Laughing Gas, Xiao Qi, 笑气
An 1-hour session of inhaled nitrous oxide at concentrations of 50%.
PlaceboDrug
Also called Air oxygen mixture
An 1-hour session of mixed oxygen-air gas(inspired oxygen concentration ~50%)
| Study group | Role | What they receive |
|---|---|---|
| Air oxygen mixture | Placebo comparator | participants in this arm inhale mixed oxygen-air gas (inspired oxygen concentration ~50%). Receives: Drug: Placebo |
| Nitrous oxide | Experimental | Participants in this group inhale mixed 50% nitrous oxide and 50% oxygen. Receives: Drug: Nitrous Oxide |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Hamilton Depression Rating Scale-17 item (HDRS-17)
Interview-based questionnaire used to measure the severity of depression. Consists of 17 items with a score calculated. Higher scores are associated with more severe depression.
0 - 7 = Normal; 8 - 17 = Mild Depression; 18 - 24 = Moderate Depression; > 25 = Severe Depression; Maximum score = 52
Measured: Baseline, 2hours, 24hours, 7days, 2weeks
Change in QIDS-16-SR (Quick Inventory of Depressive Symptomatology-16 Self Report)
This is a 16-item self report questionnaire that measures depressive symptoms. Improvement is reported in change in depressive score score ranges from 0-27, with higher numbers indicating more severe symptom reporting.
Change is calculated by baseline plus/minus the value at the later time point
Measured: Baseline, 2hours, 24hours, 7days, 2weeks
Change in Visual Analog Scale-Depression (VAS-D)
All patients are asked to fill out visual analog scale for depression (VAS-D) before and after the intervention. VAS-D is a self-report scale for ddepression severity, with 0 score indicating not at all depressed and 10 score indicating extremely depressed.
Measured: Baseline, 2hours, 24hours, 7days, 2weeks
Secondary outcomes (11)
Chang in Event Related Potentials (ERPs)
The investigator employ 64-lead Event Related Potentials (ERPs) to assess the resting-state EEG signal and signals during specific neurocognitive processes related to tasks, including an emotional face recognition task, a dot probe task and a self-referential personality word memory task.
Measured: Baseline, 24hours, 7days, 2weeks
Change in voxel-based morphometry of grey matter, white matter as assessed by structural magnetic resonancce imaging.
Participants will receive resting-state functional magnetic resonance imaging (MRI). Scans will be performed on a 3.0-T Siemens Magnetom Skyra scanner (Siemens Healthineers, Erlangen, Germany). During scanning, all participants were instructed to remain motionless, and to think of nothing in particular but to not fall asleep.
Measured: Baseline, 24hours
Change in Functional connectivity
Change in Functional connectivity of the brain networks between baseline and after the inhaled Nitrous oxide 24hours as assessed by measure of connectivity in multimodal MRI.
Measured: Baseline, 24hours
Change in peripheral blood cytokines
Peripheral blood sample will be collected and the concentration of IL-6, TNF-α, and CRP will be assessed.
Measured: Baseline, 2hours, 24hours
Change in feces bacterial flora
The objective of investigator is to characterize gut microbiome in patients with TRD. To explore the specific diversity of gut microbiome.
The stool samples were collected in the collection kits at the baseline, and were frozen at -80 °C. After the process of DNA Purification, 16S rRNA Gene Amplification and Illumina MiSeq sequencing, the study finally find the abundance and diversity of microbiota.
Measured: Baseline
Change in the TMT/A and B (Executive Function)
Trail Making Test (TMT) is a cognitive test designed to assess scanning, visuomotor tracking, executive function, and cognitive flexibility. It consists of two parts, A and B: the patient must draw lines to connect consecutively numbered circles (part A) and then connect consecutively numbered and lettered circles alternating between the two sequences (part B). The time taken to complete the two parts is recorded. Part A assesses cognitive processing speed. The lower the score the faster the processing speed.
Measured: Baseline, 24hours, 7days, 2weeks
Change in Congruent STROOP Time to Complete (Executive Function)
Stroop Colour Naming Test (STROOP) is a cognitive test designed to assess the ability to inhibit a prepotent response to reading words while performing a task that requires attention control. It comprises two sheets with 50 words on each, and each word is the name of a colour. On the first sheet, the Congruent STROOP Sheet, the word and ink colour match; on the Incongruent STROOP Sheet, the word and ink colour do not match. For each sheet, the patient has 4 minutes to name the ink colour of each word. When the patient finishes the sheet, or once 4 minutes is up, the clinician notes the time taken and counts the number of correct and incorrect responses. The scale ranges from 0-100, the higher score the greater the cognitive flexibility.
Measured: Baseline, 24hours, 7days, 2weeks
Digit-Span Test
Score range 0-12 for each of for dimensions: Digit span forward, digit span backward, block span forward, block span backward. Higher scores indicate better cognitive performance.
Measured: Baseline, 24hours, 7days, 2weeks
Change in DSST (Number of Correct Symbols)
Digit Symbol Substitution Test (DSST) is a cognitive test designed to assess psychomotor speed of performance requiring visual perception, spatial decision-making, and motor skills. It consists of 133 digits and requires the patient to substitute each digit with a simple symbol in a 90-second period. Each correct symbol is counted, and the total score ranges from 0 (less than normal functioning) to 133 (greater than normal functioning)." as a description of DSST.
Measured: Baseline, 24hours, 7days, 2weeks
Improvement on Snaith-Hamilton Pleasure Scale (SHAPS)
The Snaith-Hamilton Pleasure Scale (SHAPS) assesses the anhedonia symptoms of MDD patients, with higher score indicating more severe anhedonia.
Evaluating the patient's pleasure experience and choosing the degree of agreement with the happy response in some pleasant situations, and each item was rated on a 4-point scale."1 = Strongly agree, 2 = agree, 3 = disagree and 4 = strongly disagree" This scale evaluates the status of patients in the recent period of time, The total score of the scale is the sum of the scores of 14 items, with a total score of 14-56. The higher the total score, the more serious the anhedonia.
Measured: Baseline, 2hours, 24hours, 7days, 2weeks
Change in Hamilton Anxiety Rating Scale (HAM-A)
Assessed via the Hamilton Anxiety Rating Scale (HAM-A). The HAM-A score ranges from 0 (no present anxiety) to 56 (maximum anxiety score).
Measured: Baseline, 2hours, 24hours, 7days, 2weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 May 2019
- Study start1 Apr 2019
- Primary completion31 Mar 2021
- Study completion31 Mar 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Depressive DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 44 participants (actual)
Sponsor and investigators
- Lead sponsor
- Lingjiang Li
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Lingjiang Li, Central South University
- Investigators
- Lingjiang Li, MD, Principal investigator, Mental Health Institute, the Second Xiangya Hospital of Central South University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03932825
- Sponsor's protocol ID
- 18-05-04-XY-0001
- Status last verified
- Apr 2021
- First submitted
- 20 Apr 2019
- Last updated
- 8 Apr 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Apr 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Trial of Nitrous Oxide for Treatment-Resistant Major Depressive Disorder
- ClinicalTrials.gov ID
- NCT03932825
- Acronym / sponsor ID
- 18-05-04-XY-0001
- Conditions
- Depressive Disorder, Major Depressive Disorder, Treatment Resistant Depression, Depressive Disorder, Major, Depression
- Keywords
- Nitrous Oxide, Laughing Gas
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 44 participants (actual)
- Lead sponsor
- Lingjiang LiUniversity, hospital or other
- Study start
- 1 Apr 2019 (actual)
- Primary completion
- 31 Mar 2021 (actual)
- Study completion
- 31 Mar 2021 (actual)
- First posted
- 1 May 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims at investigating the persistence of antidepressant effect of Nitrous Oxide (N2O) for Treatment-Resistant Depression(TRD). The investigators also aim to assess the effect of N2O on the electroencephalograph, multimodal magnetic resonance imaging(MRI), blood cytokines, feces bacteria flora and neuropsychological performance in patients with TRD. The investigators further aim to identify the predictors of N2O's antidepressant effeect using the above techniques.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Air oxygen mixture | Placebo comparator | Drug: Placeboparticipants in this arm inhale mixed oxygen-air gas (inspired oxygen concentration ~50%). |
| Nitrous oxide | Experimental | Drug: Nitrous OxideParticipants in this group inhale mixed 50% nitrous oxide and 50% oxygen. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Adult (≥18 years, both sexes), with ICD-10 criteria for MDD without psychosis, as determined by a structured clinical interview Mini International Neuropsychiatric Interview
- Moderate to severe depression, as defined by a pretreatment score >17 on the HDRS-17 scale
- TRD was defined as having had at least two adequate dose-duration, antidepressant medication failures in the current episode and a lifetime failure of at least three antidepressant medication trials.
- Informed consent to participate in this study
Key exclusion criteria (9 listed)
- A history of bipolar disorder, schizophrenia, schizoaffective disorder, obsessive-compulsive disorder, panic disorder, or documented Axis II diagnoses; active suicidal intention, as determined by clinical interview
- Active or recent (<12 months) substance abuse or dependence; excluding nicotine
- Presence of acute medical illness that could interfere with study participation, including significant pulmonary disease
- Acute severe suicidal ideation
- Acute psychosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nitrous OxideAlso: Laughing Gas, Xiao Qi, 笑气An 1-hour session of inhaled nitrous oxide at concentrations of 50%. | Drug | Nitrous oxide |
| PlaceboAlso: Air oxygen mixtureAn 1-hour session of mixed oxygen-air gas(inspired oxygen concentration ~50%) | Drug | Air oxygen mixture |
Primary outcome
Change in Hamilton Depression Rating Scale-17 item (HDRS-17)
Time frame: Baseline, 2hours, 24hours, 7days, 2weeks
Interview-based questionnaire used to measure the severity of depression. Consists of 17 items with a score calculated. Higher scores are associated with more severe depression. 0 - 7 = Normal; 8 - 17 = Mild Depression; 18 - 24 = Moderate Depression; > 25 = Severe Depression; Maximum score = 52
Change in QIDS-16-SR (Quick Inventory of Depressive Symptomatology-16 Self Report)
Time frame: Baseline, 2hours, 24hours, 7days, 2weeks
This is a 16-item self report questionnaire that measures depressive symptoms. Improvement is reported in change in depressive score score ranges from 0-27, with higher numbers indicating more severe symptom reporting. Change is calculated by baseline plus/minus the value at the later time point
Change in Visual Analog Scale-Depression (VAS-D)
Time frame: Baseline, 2hours, 24hours, 7days, 2weeks
All patients are asked to fill out visual analog scale for depression (VAS-D) before and after the intervention. VAS-D is a self-report scale for ddepression severity, with 0 score indicating not at all depressed and 10 score indicating extremely depressed.
11 secondary outcomes
Chang in Event Related Potentials (ERPs)
Time frame: Baseline, 24hours, 7days, 2weeks
Change in voxel-based morphometry of grey matter, white matter as assessed by structural magnetic resonancce imaging.
Time frame: Baseline, 24hours
Change in Functional connectivity
Time frame: Baseline, 24hours
Change in peripheral blood cytokines
Time frame: Baseline, 2hours, 24hours
Change in feces bacterial flora
Time frame: Baseline
Change in the TMT/A and B (Executive Function)
Time frame: Baseline, 24hours, 7days, 2weeks
Change in Congruent STROOP Time to Complete (Executive Function)
Time frame: Baseline, 24hours, 7days, 2weeks
Digit-Span Test
Time frame: Baseline, 24hours, 7days, 2weeks
Change in DSST (Number of Correct Symbols)
Time frame: Baseline, 24hours, 7days, 2weeks
Improvement on Snaith-Hamilton Pleasure Scale (SHAPS)
Time frame: Baseline, 2hours, 24hours, 7days, 2weeks
Change in Hamilton Anxiety Rating Scale (HAM-A)
Time frame: Baseline, 2hours, 24hours, 7days, 2weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Apr 2021.
- Individual participant dataSharing planned: No
Related trials for Depressive Disorder
Not yet recruitingObservational study
Validation of Wearable Core Body Temperature-Based Circadian Rhythm Digital Biomarkers
Mood Disorders, Major Depressive Diorder
RecruitingObservational study
A Prospective Study of Anxiety, Depression, and Bipolar Disorder in People
Anxiety Disorders, Depressive Disorder
RecruitingPhase 3
A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder
Major Depressive Disorder
Recruiting
Anticipated Patient and Caregiver Burden
Amyotrophic Lateral Sclerosis
Recruiting
A Study of Brief Behavioral Activation for the Treatment of Depression in Older Adult Cancer Survivors
Survivorship
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lingjiang Li, MD principal investigator
Mental Health Institute, the Second Xiangya Hospital of Central South University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Nitrous Oxide in people with Depressive Disorder and Major Depressive Disorder, run by Lingjiang Li at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Apr 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Hamilton Depression Rating Scale-17 item (HDRS-17) (time frame: Baseline, 2hours, 24hours, 7days, 2weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Apr 2021.